CANF

Market-moving news on Can-Fite BioPharma (CANF): filings, earnings, deals and other events, from REDFILED.

Can-Fite is developing Namodenoson for advanced liver and pancreatic cancer.

CANF

CAN-FITE Sees Longer-Than-Expected Survival in Phase III Liver Cancer Trial

Israeli biotech reports a $4.6 million half-year loss and says blinded survival in its pivotal Namodenoson HCC study is running longer than assumed.